Lymphovascular Invasion Is Associated with Reduced Locoregional Control and Survival in Women with Node-Negative Breast Cancer Treated with Mastectomy and Systemic Therapy

LVI is an adverse prognostic factor for relapse and survival in node-negative patients treated with mastectomy and systemic therapy. LVI, in combination with age older than 50 years, premenopausal status, grade III histology, or estrogen receptor-negative disease, identified patient subsets with 7-year LRR risks of approximately 15% to 20%. Prospective research is required to define the role of adjuvant radiotherapy in these patients.